An Updated Meta-analysis of 23 Case-control Studies on the Association Between MiR-34b/c Polymorphism and Cancer Risk

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 19

PMID 28415817

Citations 4

Authors

Hua Li

Shuling Diao

Jingsen Li

Baoxin Ma

Shuanghu Yuan

Affiliations

Soon will be listed here.

Abstract

The association between in microRNA-34b/c gene rs4938723 polymorphisms and cancer risk remains inconclusive. This meta-analysis was performed to analyze the association between microRNA-34b/c rs4938723 polymorphism and risk for cancer development. In total, 304 studies from PubMed, Embase, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases were examined, and 23 studies were included in this meta-analysis. The 23 selected studies involved 10,812 cancer cases and 11,719 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. Our results indicate a significant association between the rs4938723 polymorphism and cancer risk in the overdominant model (P heterogeneity = 0.018, OR = 1.093, and 95% CI = 1.015-1.177 for CT vs. CC/TT). Using a stratified subgroup analysis, rs4938723 polymorphisms were associated with an increased risk for hepatocellular carcinoma, but decreased risk for colorectal, gastric, and esophageal squamous cell cancer. These findings indicate that the rs4938723 gene is a susceptible locus for cancer.

Citing Articles

Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.

Tian J, Liu G, Zuo C, Liu C, He W, Chen H Cancer Biol Med. 2019; 16(2):361-389.

PMID: 31516756 PMC: 6713634. DOI: 10.20892/j.issn.2095-3941.2018.0290.

Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies.

Tian J, Liu C, Liu G, Zuo C, Chen H Cancer Med. 2019; 8(3):1289-1305.

PMID: 30793520 PMC: 6434199. DOI: 10.1002/cam4.1972.

Rs4938723 Polymorphism Is Associated with Susceptibility to Hepatocellular Carcinoma Risk and Is a Protective Factor in Leukemia, Colorectal, and Esophageal Cancer.

Xu B, Zhu Y, Tang Y, Zhang Z, Wen Q Med Sci Monit. 2018; 24:7057-7071.

PMID: 30286050 PMC: 6183103. DOI: 10.12659/MSM.912534.

Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

He J, Zou Y, Liu X, Zhu J, Zhang J, Zhang R Mol Ther Nucleic Acids. 2018; 11:1-8.

PMID: 29858046 PMC: 5849804. DOI: 10.1016/j.omtn.2018.01.003.

References

Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y . Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study. Medicine (Baltimore). 2015; 94(38):e1536. PMC: 4635749. DOI: 10.1097/MD.0000000000001536. View

Sanaei S, Hashemi M, Rezaei M, Hashemi S, Bahari G, Ghavami S . Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk. Biomed Rep. 2016; 5(1):125-129. PMC: 4906800. DOI: 10.3892/br.2016.690. View

Yang C, Ma X, Liu D, Wang Y, Tang R, Zhu Y . Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population. Tumour Biol. 2014; 35(12):12545-54. DOI: 10.1007/s13277-014-2574-9. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Son M, Jang M, Jeon Y, Kim W, Kwon C, Ko K . Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013; 524(2):156-60. DOI: 10.1016/j.gene.2013.04.042. View

Guo J, Jin M, Zhang M, Chen K . A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One. 2012; 7(1):e30585. PMC: 3265498. DOI: 10.1371/journal.pone.0030585. View

Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q . Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One. 2013; 8(3):e58564. PMC: 3596299. DOI: 10.1371/journal.pone.0058564. View

Zhu J, Yang L, You W, Cui X, Chen Y, Hu J . Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China. Int J Clin Exp Pathol. 2015; 8(6):7332-40. PMC: 4525967. View

Li L, Wu J, Sima X, Bai P, Deng W, Deng X . Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol. 2013; 34(3):1919-23. DOI: 10.1007/s13277-013-0736-9. View

10.

Li H, Li X, Ge X, Jia L, Zhang Z, Fang R . MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A. Oncotarget. 2016; 7(34):54838-54851. PMC: 5342385. DOI: 10.18632/oncotarget.10761. View

11.

Wang L, Kwong Y, Wong K, Kho C, Jin D, Tse E . Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J Transl Med. 2014; 12:52. PMC: 3941938. DOI: 10.1186/1479-5876-12-52. View

12.

Chandra V, Lee Y, Gupta U, Mittal B, Kim J, Rai R . Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis. Oncotarget. 2016; 7(45):74286-74302. PMC: 5342053. DOI: 10.18632/oncotarget.10951. View

13.

Lin Z, Chen L, Song M, Shi K, Tang K . Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis. Asian Pac J Cancer Prev. 2014; 15(17):7251-5. DOI: 10.7314/apjcp.2014.15.17.7251. View

14.

Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A . Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013; 19(24):6842-52. PMC: 4161219. DOI: 10.1158/1078-0432.CCR-13-0736. View

15.

Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J . A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2010; 128(2):412-7. DOI: 10.1002/ijc.25342. View

16.

Hiyoshi Y, Schetter A, Okayama H, Inamura K, Anami K, Nguyen G . Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. PLoS One. 2015; 10(4):e0124899. PMC: 4404052. DOI: 10.1371/journal.pone.0124899. View

17.

Oh J, Kim J, Lee B, Jang M, Chong S, Park P . Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep. 2013; 31(2):995-1002. DOI: 10.3892/or.2013.2926. View

18.

Yuan Z, Li J, Hu R, Jiao Y, Han Y, Weng Q . Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. Sci Rep. 2015; 5:16482. PMC: 4653744. DOI: 10.1038/srep16482. View

19.

Wang Y, Han Y, Weng Q, Yuan Z . Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. Oncotarget. 2016; 7(40):65770-65781. PMC: 5323191. DOI: 10.18632/oncotarget.11664. View

20.

Vogt M, Munding J, Gruner M, Liffers S, Verdoodt B, Hauk J . Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011; 458(3):313-22. DOI: 10.1007/s00428-010-1030-5. View